In a significant advancement for antifungal therapy, Napp Pharmaceuticals Limited, a key player within the international network of Mundipharma independent associated companies, has announced the authorization of Rezafungin by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of invasive candidiasis in adults in Great Britain. This approval is a testament to the […]
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing life-saving therapies, announced a significant breakthrough with the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) approving REZZAYO (rezafungin acetate) for invasive candidiasis treatment in adults. This announcement is a major advancement in healthcare, addressing a critical need for new treatments in […]
